Results 21 to 30 of about 1,869 (168)

Therapy with lebrikizumab for refractory peristomal irritant contact dermatitis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Olivia Danneil, Joachim Dissemond, Finja Reinboldt‐Jockenhöfer   +2 more
openaire   +3 more sources

Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis [PDF]

ClinicoEconomics and Outcomes Research
Hamad AlmutlaqDepartment of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi ArabiaCorrespondence: Hamad Almutlaq, Department of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam ...
Almutlaq H
doaj   +2 more sources

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials [PDF]

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe ...
Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger   +11 more
doaj   +2 more sources

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence [PDF]

Dermatology and Therapy
Introduction Real-world management of moderate-to-severe atopic dermatitis (AD) may involve treatment interruptions. This indirect comparison evaluated the efficacy of lebrikizumab, dupilumab, and tralokinumab monotherapy in achieving week-52 response at
Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya   +16 more
doaj   +2 more sources

Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Ana Beatris Rossi, Nick Freemantle, Mike Bastian   +2 more
exaly   +2 more sources

Atopic Dermatitis Successfully Treated with Lebrikizumab in Real-World Clinical Practice in Czech Republic: A Case Series [PDF]

Dermatology and Therapy
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with impaired quality of life and a substantial burden of disease. Lebrikizumab is a monoclonal antibody that selectively binds with high affinity to interleukin-13, thereby ...
Marie Jandová, Radek Litvik, Martin Tichý, Spyridon Gkalpakiotis   +3 more
doaj   +2 more sources

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) affects multiple areas of the body, some of which may be more refractory to treatment. We evaluated improvements in the Eczema Area and Severity Index (EASI) by body region and clinical signs for each body region in ...
Eric L. Simpson, Marjolein de Bruin-Weller, H. Chih-ho Hong, Delphine Staumont-Sallé, Andrew Blauvelt, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, Zhuqing Liu, Helena Agell, Jonathan I. Silverberg   +14 more
doaj   +4 more sources

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +2 more sources

Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre [PDF]

Dermatology and Therapy
Introduction Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions.
Azmeralda Abraheem, Neenu Sebastian, Firas C. Kreeshan, Tim H. Clayton, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +2 more sources

Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison [PDF]

Dermatology and Therapy
Introduction A matching-adjusted indirect comparison evaluated the short-term efficacy of lebrikizumab plus topical corticosteroids (TCS) versus dupilumab plus TCS in adults with moderate-to-severe atopic dermatitis (AD).
Raj Chovatiya, April Armstrong, Leon Kircik, Lluís Puig, Mark G. Kirchhof, Tiago Torres, Yousef Binamer, Gleison Duarte, Bülent Akmaz, Martin Dossenbach, Gaia Gallo, Chao Yang, Lucia Seminario-Vidal, Yuxin Ding, Jonathan I. Silverberg   +14 more
doaj   +2 more sources